Search…

Bo Medical-B (02142.HK) announced its interim performance, achieving revenue of approximately 101 million US dollars, representing a year-on-year growth of approximately 3.27 times.

28/08/2025

Smart Finance App news, Hebao Pharmaceuticals-B (02142.HK) announced its mid-term performance for 2025, with revenue of approximately $101 million USD, a year-on-year increase of about 3.27 times; net profit during the period was $72.99 million USD, a year-on-year increase of 51.25 times; earnings per share were $0.09 USD.

Latest

2 m ago

Hainan Huatie (603300.SH) released its performance for the first half of the year, with a net profit attributable to the owner of the parent company of 341 million yuan, an increase of 1.85%.

2 m ago

Increase investment and layout in the computing power business, Hongjing Technology (301396.SZ) plans to raise no more than 1.354 billion yuan through private placement.

2 m ago

Brazilian Steel Industry Lobby Group ACO Brasil: It is expected that Brazil's crude steel production will decrease by 0.8% in 2025 compared to 2024, previously estimated to decrease by 0.6%.

2 m ago

Brazil's steel industry lobbying group, ACO Brasil, expects that Brazil's crude steel production will decrease by 0.8% in 2025 compared to 2024, a larger decrease than the previously anticipated 0.6% decline.

3 m ago

China Life Insurance (601628.SH) released its performance for the first half of the year, with a net profit attributable to shareholders of 40.931 billion yuan, an increase of 6.9% year-on-year.

See all latest